Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Meet the Leaders (38)
November 22, 2004
- Shionogi: Profits Up Sharply Despite Decline in Sales
November 15, 2004
- Korosho Withdraws Recommendations for Antibiotics Skin Tests: Safety Info
November 15, 2004
- Santen: Sales Down 2.3% to \45.0 Bil.
November 15, 2004
- Chugai Ready to Supply Tamiflu for 15 Mil. Patients
November 15, 2004
- Expecting New Products to Spark Recovery: Mr Morita of Daiichi
November 15, 2004
- REGULATORY NEWS IN BRIEF
November 15, 2004
- Tanabe to Focus on Remicade in Near-term Strategy: Mr Hayama
November 15, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 15, 2004
- Dainippon: Declines in Sales, Profits due to NHI Price Reduction
November 15, 2004
- The 5th Kitasato University-Harvard School of Public Health Symposium
November 15, 2004
- Torii: Sales Up 1.5% to \21.9 Bil.
November 15, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 15, 2004
- Teijin: Med., Pharm Business Sales Up 3.2% to \47.4 Bil.
November 15, 2004
- Monitor
November 15, 2004
- Gene Chip Accounts for 65% of Affymetrix Japan's Sales
November 15, 2004
- DIAGNOSTIC NEWS IN BRIEF
November 15, 2004
- PhRMA Publishes Japanese Version of Principles for Conducting Clinical Trials
November 15, 2004
- OTC NEWS IN BRIEF
November 15, 2004
- Mediceo HD Forms Capital Tie-up with Chain Management
November 15, 2004
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…